NEUP Stock Overview

NEUP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Earnings have declined by 31.3% per year over past 5 years

Makes less than USD$1m in revenue ($0)

My Notes

Capture your thoughts, links and company narrative

Neuphoria Therapeutics Inc. Competitors

Moderna

NasdaqGS:MRNA

US$15.5b

BioNTech

NasdaqGS:BNTX

US$27.4b

Revolution Medicines

NasdaqGS:RVMD

US$7.5b

Summit Therapeutics

NasdaqGM:SMMT

US$14.0b

Price History & Performance

Summary of share price highs, lows and changes for Neuphoria Therapeutics
Historical stock prices
Current Share Price	US$6.63
52 Week High	US$10.50
52 Week Low	US$3.75
Beta	0.27
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	NEUP	US Biotechs	US Market
7D	n/a	-3.3%	-0.4%
1Y	n/a	-2.7%	24.8%

Return vs Industry: Insufficient data to determine how NEUP performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how NEUP performed against the US Market.

Price Volatility

Is NEUP's price volatile compared to industry and market?
NEUP volatility
NEUP Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: NEUP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine NEUP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	16	Spyros Papapetropoulos	www.bionomics.com.au

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Neuphoria Therapeutics Inc. Fundamentals Summary

How do Neuphoria Therapeutics's earnings and revenue compare to its market cap?
NEUP fundamental statistics
Market cap	US$14.09b
Earnings (TTM)	-US$10.82m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is NEUP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NEUP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$10.82m
Earnings	-US$10.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did NEUP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 15:33
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neuphoria Therapeutics Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tanushree Jain	Bell Potter
Esther Lannie Hong	Berenberg
Charles Duncan	Cantor Fitzgerald & Co.